Exploratory trial to examine the safety and effectiveness of transdermal electrical stimulation for retinitis pigmentosa - Exploratory trial to examine the safety and effectiveness of transdermal electrical stimulation for retinitis pigmentosa

Chiba university hospital0 sites10 target enrollmentJuly 12, 2017

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Chiba university hospital
Enrollment: 10
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 12, 2017

End Date

February 20, 2018

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Chiba university hospital

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•cases who conflict with any of the following must not include this study. (1\) Patients complicated of macular lesions such as vitreous macular traction syndrome, macular edema, epiretinal membrane, and myopia with posterior staphyloma associated with myopia (2\) Patients undergoing internal eye surgery within 3 months (3\) Patients who changed the dose and usage of isopropyl unoprostone, calcium antagonist, dark adaptation improving drug within 31 days before screening (4\) Patients who have a history of drug allergy to drugs to be used during the trial period (mydriatic drugs, eye drops anesthetics, etc.) (5\) Patients complicated with diabetic retinopathy (6\) Patients who are currently complaining of external eye inflammation, infection, or severe dry eye (7\) Patients who may be pregnant or pregnant. Patient who is breastfeeding. Patients who want pregnancy during the trial period (8\) Patients with a history of optic nerve disease (9\) Evaluation of efficacy nuclear cataract with moderate degree (grade 3 in Emery classification) to the eyes, patients with complication of anterior subcapsular, subcapsular cataract, or late cataract which have a serious effect on vision (10\) Patients whose Mean Deviation (MD) value of HFA 10\-2 has deteriorated by 3 dB or more per year (11\) Patients who have not seen any deterioration in visual acuity, OCT findings, dynamic visual field inspection (Gp) findings, and visual field sensitivities at HFA 10\-2 in the last 3 years (12\) Patients currently participating in other clinical trials (13\) patients under investigational responsibility (shared) doctors judged inappropriate for participation in this trial